Free Trial
OTCMKTS:INNVD

Innovus Pharmaceuticals (INNVD) Stock Price, News & Analysis

Innovus Pharmaceuticals logo

About Innovus Pharmaceuticals Stock (OTCMKTS:INNVD)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
4,300 shs
Average Volume
9,592 shs
Market Capitalization
$7.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive INNVD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innovus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INNVD Stock News Headlines

What a Former CIA Agent Knows About the Coming Collapse
This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained to stay alive when systems collapse. In Operation Gold Rush, Jason Hanson reveals how gold and silver saved his life—and how they could protect yours in the next crisis. You’ll learn how to hide gold like a covert operative, secure your 401(k) in physical assets, and prepare for grid failures, economic collapse, or worse.tc pixel
See More Headlines

INNVD Stock Analysis - Frequently Asked Questions

Innovus Pharmaceuticals Inc (OTCMKTS:INNVD) posted its quarterly earnings results on Monday, April, 1st. The company reported ($0.99) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.12. The firm earned $4.75 million during the quarter, compared to analysts' expectations of $8.13 million. Innovus Pharmaceuticals had a negative trailing twelve-month return on equity of 682.54% and a negative net margin of 34.51%.

Shares of INNVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
4/01/2019
Today
9/16/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:INNVD
CIK
N/A
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($4.16)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.28 million
Net Margins
-34.51%
Pretax Margin
N/A
Return on Equity
-682.54%
Return on Assets
-78.57%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.68
Quick Ratio
0.36

Sales & Book Value

Annual Sales
$23.99 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.05 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
2,356,000
Free Float
N/A
Market Cap
$7.07 million
Optionable
Not Optionable
Beta
2.89

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (OTCMKTS:INNVD) was last updated on 9/16/2025 by MarketBeat.com Staff
From Our Partners